Therapy with docetaxel micellar in metastatic, castration-resistant prostate cancer

SAKK 67/20

Coordinating investigator

Dr. med.
Istituto Oncologico della Svizzera Italiana (IOSI)
+41 91 811 91 11

In trial SAKK 67/20 patients with metastatic, castration-resistant prostate cancer (mCRPC) are given the newly developed active substance docetaxel micellar, which is thought to cause fewer side effects than conventional docetaxel. One of the trial objectives is to identify the highest possible dose which is still tolerated well.

Treatment with docetaxel is one of the standard therapies for patients with mCRPC. However, the conventional delivery form of docetaxel can also cause side effects. A new delivery form of docetaxel (docetaxel micellar) has now been developed. Docetaxel micellar is expected to cause fewer side effects than conventional docetaxel.

In trial SAKK 67/20 the safety, tolerability and effect of different doses of docetaxel micellar are being investigated in patients with mCRPC. These aspects have already been investigated in two clinical trials, but only in patients with breast cancer. In those trials the effect of docetaxel micellar was comparable to that of docetaxel, but the safety profile was more favorable overall. Docetaxel micellar is not currently authorized for the treatment of prostate cancer in any country.

A maximum of 18 patients with mCRPC who have not already undergone chemotherapy can take part in the trial.


All trials